Pfizer Inc

NYSE: PFE
$29.22
-$0.05 (-0.2%)
Closing Price on October 18, 2024

PFE Articles

March 11, 2016: Markets opened higher again on Friday and held on to the early gains all day. Energy and financials stocks led the gainers and only 2 of 10 sectors posted losses: consumer staples and...
24/7 Wall St. screened the Merrill Lynch research data base for solid growth ideas that also paid a dividend of at least 4%.
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
Most of the stocks traded on the New York Stock Exchange with the greatest number of shares short saw their short interest decline between the February 12 and February 29 settlement dates.
The top analyst upgrades, downgrades and initiations seen on Tuesday, March 8, include AutoNation, Celldex Therapeutics, EP Energy, Shopify, Sony, Urban Outfitters and Valeant Pharmaceuticals.
So far this year, based on changes in yields, the Dogs of the Dow are doing much better, as their yields have not widened out near as much as the other 20 Dow companies.
February 29, 2016: Markets opened lower on Monday before rising to intra-day highs at around noon, and then dipping to a loss by mid-afternoon. Healthcare and energy stocks were the biggest losers...
With investors looking for safety and dividends for total return, the big pharmaceutical stocks are just the ticket, and these four are outstanding.
February 26, 2016: Markets opened higher on Friday on rising oil prices in Asia and Europe which turned into lower prices as the trading day went along. Basic materials and financials were today’s...
For the long haul, these three stock should provide a much better avenue for total return and continue to increase dividend payouts.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
The most shorted stock traded on the New York Stock Exchange — Chesapeake Energy — bucked the short interest trend with a modest gain in February.
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.